Biosimilars 2010

Welcome to

2^nd World Congress on BIOSIMILARS

Recent Advances in Anemia, Oncology, Thrombosis, Neurology and Virology

A Slow Rising Wave or a Storm?

June 10, 2010 - Paris, France

Establish Solutions to Developmental and Strategic Issues for Pharma Biotech Manufacturers

Provide the Pharmacologic and Medical Knowledge to Physicians becoming fully aware about Mains Challenge and Outcomes for their daily activity

Dear Colleagues,

-

On behalf of the Scientific Committee, we are pleased to announce the organization of the 2^nd Biosimilars Conference which will be held the 10^th June 2010 in Paris.

Within the next two years, pharma market forecasts predict that biopharmaceuticals will amount to more than 50% of newly approved medicines. In addition to a growing market share, a substantial number of major biotechnology based drugs (rhu-EPO, Darbepoetin alfa, monoclonal antibodies….) will come off patent and enable the development of new biosimilar products. US’governance aims to set up specific guidelines for Biosimilars (F.O.B : Follow On Biologic) :  this  new scenario provides opportunities for companies considering biosimilar as a priority for growing in pharmaceutical market. 

While this facilitates a great range of business opportunities, biosimilar manufacturers face high economic risk and need to come up with an innovative business models. In addition, it is crucial for them to ensure that their R&D and production processes guarantee safety and efficacy of their products. As some regulatory issues like interchangeability have not been resolved, manufacturers are particularly forced to come up with a strong and innovative marketing strategy convincing physicians and handling pricing as well as reimbursement issues effectively with regulatory authorities.

The 1^st annual Biosimilars conference provided insights on :

- Biosimilar market (rhu-GH, rhu-EPO, GCSF, Insuline et analogues, HBPM)

- The successfull strategy for the different actors through Epoetin alfa’s

  biosimilar experience

- The EMEA guidelines and the French national scientific society position

The aims of Biosimilars 2010 are to :

-Establish solutions to both developmental and strategic issues for pharma biotech manufacturers

-Provide the pharmacologic and medical knowledge to physicians becoming fully aware about mains challenges and outcomes for their daily activity through lecture and case study driven presentations from leading pharma biotech manufacturers and relevant point of view from expert in their area.

This event will provide best practice solutions to help the main actors to resolve their existing and upcoming challenges in this market.

A series of interactive roundtable discussions will follow each lecture.

Among Speakers: